Find Funding Opportunities
COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.
Learn more about award types and program directors and managers.
NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!
For more focused results add quotes to indicate parameters. Example format: "search term".
Countermeasures Against Chemical Threats CounterACT): Opportunities Opioid Research Notice Number: NOT-NS-18-019 Key Dates Release Date: November 27, 2017 Related Announcements PAR-15-315 PAR-16-330 PAR-16-331 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Drug Abuse NIDA) Purpose purpose this notice to highlight NIH/NINDS Countermeasures Against Chemical Threats CounterACT) program's interest developing safe effective therapeutics would prevent morbidity mortality following exposure the opioids fentanyl, carfentanil, acetylfentanyl, alfentanil, and/or diacetylmorphine heroin). program concentrates developing therapeutics treat and/or prevent injuries deaths may result exposure chemical threats a variety scenarios. Applications being accepted under three specific Funding Opportuntiy Announcements FOAs) issued the NIH CounterACT program PAR-15-315, PAR-16-330, PAR-16-331). be considered appropriate these FOAs, applications must follow instructions general descriptions found these FOAs well the following requirements related the specialized mission the NIH CounterACT program. Research supported these FOAs must relevant chemical emergencies where general civilian population might exposed opioids. research might include industrial accidents, natural disasters causing casualties, deliberate attacks again civilians. examples research could supported include, are limited to, following: Safety efficacy studies naloxone other FDA-approved drugs use against opioids listed above, especially they relate potential respiratory problems Safety efficacy studies naloxone other FDA-approved drugs use against opioids listed above these opioids administered a method consistent a deliberate attack against civilians, by industrial accidents natural disasters causing mass casualties e.g. aerosolized, food water, etc.) opioid overdose antidotes greater safety efficacy naloxone other FDA- approved drugs match higher potency fentanyl analogues, including naloxone-related antidotes those based new therapeutic targets Antidotes longer half-lives that multiple doses not needed rapid succession, many people be treated once during mass casualty event; includes increases serum half-life well alteration degradative metabolism Single antidotes acceptable activity against least or of opioids listed above NIH CounterACT program support exploratory developmental research PAR-15-315) well the identification PAR-16-330) optimization PAR-16-331) therapeutic lead compounds. Potential applicants should the descriptions scientific scope found these FOAs. Applicants strongly urged contact NIH representatives listed below prior submission. Inquiries Please direct general NIH CounterACT inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-6035 Email: david.jett@nih.gov Please direct specific opioid research inquiries: Kristopher J. Bough, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-9800 Email: boughk@nih.gov nbsp;